Richard Wilson

Richard Wilson is currently the Senior Vice President, Primary Focus Lead for Genetic Regulation at Astellas where he is responsible for setting and leading the AAV gene therapy strategy for Astellas along with accountability for a broad portfolio of clinical and preclinical treatments for a range of serious genetic conditions in neuromuscular, CNS and cardiac diseases.

Richard has over 30 years of experience in research, development, and commercialization of small molecules, biologics, and gene therapies. Prior to Astellas, Richard has held leadership positions in a range of organizations including BioMarin Pharmaceutical, GlaxoWellcome, BioChem Pharma, Theravance and Innoviva and has delivered products to the market in diseases such as Asthma, COPD, PKU as well as leading R&D programs in anti-infective, cardiovascular, rheumatology, urology and genetic metabolic disease areas.

Richard currently serves on the board of directors of the Alliance for Regenerative Medicine and is a board observer for Taysha Gene Therapies and AviadoBio. He has also served on a variety of volunteer and non-profit entities including the board of directors for UC Berkeley Executive Education and as an industry advisor for California Life Sciences FAST initiative.

Richard holds a BSc (Hons) in Chemistry from the University of Manchester and an MBA from the Haas School of Business at the University of California, Berkeley.